Business, energy, technology, markets and global industry news from Business News Today

cisplatin-induced ototoxicity

PharmaDeviceNews cisplatin-induced ototoxicity
Representative image of an oncology infusion and hearing assessment setting, illustrating Acousia Therapeutics’ bimokalner research into preventing cisplatin-induced hearing loss in cancer patients.
Pharma & Biotech

Acousia Therapeutics’ ACOU085 signal puts Kv7.4 activation in focus for hearing loss prevention

Read how Acousia Therapeutics’ bimokalner Phase 2a signal could reshape cisplatin hearing loss prevention in adults.

Read More
Pharma & Biotech

Why Norgine’s PEDMARQSI approval in Switzerland could reshape cisplatin ototoxicity management

Swissmedic approved PEDMARQSI for cisplatin-related hearing loss in children. Read why this could reshape paediatric oncology supportive care.

Read More